DEMENTIA 1/6/16 DR TONY O’BRIEN MD FRCP. Dementia Common – 700,000 sufferers in the UK Common – 700,000 sufferers in the UK Prevalence increases with.

Slides:



Advertisements
Similar presentations
The Memory Assessment and Treatment Service (MATS)
Advertisements

 Most common and important degenerative disease of the brain  Shrinkage in size and weight of the brain  Severe degree of diffuse cerebral atrophy.
Management of Early Dementia Dr Eleanor Mullan Consultant Psychiatrist Mental Health Services for Older People South Lee, Cork Feb 2011.
Dementia Masterclass December 2013 Types of Dementia, key features, prognostic issues and when to re-refer. Dr A R McMahon ST4 Old Age Psychiatry.
Martha Stearn, MD Institute for Cognitive Health St John’s Medical Center Jackson, Wyoming.
Dementia and Aging Steven Huege, M.D Assistant Professor of Clinical Psychiatry Perelman School of Medicine at the University of Pennsylvania.
Dementia & Delirium in Surgical Patients Damian Harding Department of Geriatric Medicine February 2008.
Dementia Drugs: Mainstream and Alternative Medicines Susan Kurrle.
Dementia with Lewy Bodies
DEMENTIA By: Angela Pabon. What is Dementia? Dementia does not always mean that one has Alzheimer's disease, there are over 80 forms of dementia The definition.
NHPA’s Chapter 3. National Health Priority Areas A collaborative initiative endorsed by the Commonwealth and all state and territory governments, which.
Recognition of Dementia Syed Zaman Consultant Physician Geriatric Medicine Palmerston North Hospital.
Alzheimer’s Assessment Assessing the Cognitive-Linguistic effects of Alzheimer’s.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 22 Alzheimer’s Disease.
Understanding the Person with Dementia Oxford Brookes University What is dementia? How do we diagnose it? What can we do? Sharon Christie OPTIMA, University.
Chapter 15 - Cognitive Disorders I.Delirium Acute, temporary impairment in perception & cognition Fluctuating course.
ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.
Alzheimer’s Disease Angela Singh, PharmD Associate Professor of Pharmacy Practice Florida A&M University College of Pharmacy & Pharmaceutical Sciences.
Burcu Ormeci, MD Department of Neurology.  In the United States;  As many as 7 million people have dementia  Almost half of all people age 85 and older.
ALZHEIMER’S PART 2. AD VIDEO
Cognitive Impairment Disorders. Assessing Brain Damage  Mental status examination  Information about current behavior and thought including orientation.
Dementia in Clinical Practice Mary Ann Forciea MD Clinical Prof of Medicine Division of Geriatric Medicine UPHS Photo: Nat Geographic.
Dementia Dr Deborah Stinson Sutton CMHT for Older People
Alzheimer’s Disease Landscape
Alzheimer’s Disease Causes, Effects, and Treatments.
Non-Alzheimer’s Dementias
THE COGNITIVE DISORDERS Brian E. Wood, D.O. Associate Professor and Chair Department of Neuropsychiatry and Behavioral Sciences Edward Via Virginia College.
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
Jack Twersky, MD Medical Director CLC Durham.  Memory impairment and at least one of the following  Aphasia  Apraxia  Agnosia  Executive function.
NOW WHERE HAVE I PUT MY GLASSES? A DISCUSSION AROUND DEMENTIA Dr Marion Overton U3A SCIENCE 19TH JUNE 2015.
WHAT DO YOU REMEMBER ABOUT ALZHEIMER’S DEMENTIA?.
 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer’s is the most common form of dementia. This.
Alzheimer’s Disease By: Chelcy Branon. Facts  In 2006, there were 26.6 million sufferers worldwide  Costs 100 billion dollars per year.
COLUMBIA PRESBYTARIAN HOSPITAL CENTER
10 signs to early detection 1. Memory loss that affects daily life 2. Challenges in planning or solving problems 3. Difficulty completing projects at.
Dementia 痴呆 Jie Ming Shen, M.D., Ph.D. Department of Neurology Ruijin Hospital, SSMU.
The Dementias Dr Giles Richards Consultant Psychiatrist CFT.
Non Alzheimer's Dementias Elizabeth Landsverk, MD Geriatrician, ElderConsult Geriatric Medicine Adjunct Professor of Medicine, Stanford University.
Assessment and Diagnosis of Dementia Dr Alison Haddow.
Dementia in Clinical Practice Mary Ann Forciea MD Clinical Prof of Medicine Division of Geriatric Medicine UPHS Photo: Nat Geographic.
DEMENTIA ABDULMAJEED ALOLAYAH What is DEMENTIA ? It is a chronic global impairment of cognitive functions without disturbed consciousness.
Dementia: Alzheimer’s Disease Cyril Evbuomwan Patient Group Meeting 1 st December 2015.
Dementia Care Wendy Burnett CNS for Older People.
Alzheimer's disease M O Jamali, H Saeed & T Mathew.
Cognitive Disorders Chapter 13 Nature of Cognitive Disorders: An Overview Perspectives on Cognitive Disorders Cognitive processes such as learning, memory,
Dementia Nicholas Cascone, PA-C.
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
Orientation to Early Memory Loss. Let’s look for some answers… What is happening? What should I do? Where should I go?
Seniors with Memory Loss: A Primer Praveen Dayalu, MD Clinical Associate Professor Department of Neurology University of Michigan.
Types of Dementia Dr Bernie Coope Associate Medical Director/Honorary Senior Lecturer, Worcester University Association for Dementia Studies.
Frontotemporal Lobar Degeneration:
DEGENERATIVE DISEASES is a disease in which the function or structure of the affected tissues or organs will progressively deteriorate over time, whether.
Dementia Dr.Mansour K. Alzahrani.  Define the dementia  Discuss the prevalence of dementia  Discuss the impact of dementia on the individual and the.
The Malfunctioning Mind: Degenerative Diseases of the Brain
Anne Moore Specialist in Special Care NHS Lanarkshire PDS
Introduction to Dementia
59 year old man w visual hallucinations
Dementia with Lewy Bodies
The Malfunctioning Mind: Degenerative Diseases of the Brain
Dementia Jaqueline Raetz, M.D..
DEMENTIA Shenae Whitfield & Kate Maddock.
Neurocognitive Disorders
Unit 40 Dementia care.
Dementia Jaqueline Raetz, M.D..
Cognitive Disorders and Aging
Chapter 30 Delirium and Dementia
Chapter 93 Dementias and Related Disorders
The Memory Assessment and Treatment Service (MATS)
Chapter 25 The Elderly.
Presentation transcript:

DEMENTIA 1/6/16 DR TONY O’BRIEN MD FRCP

Dementia Common – 700,000 sufferers in the UK Common – 700,000 sufferers in the UK Prevalence increases with age Prevalence increases with age Age years years years 80+ Prevalence 1 in in 50 1 in 20 1 in 5

Dementia Chronic disorder affecting higher cortical functions, including memory, reasoning, orientation, and communication skills Chronic disorder affecting higher cortical functions, including memory, reasoning, orientation, and communication skills Gradual loss of skills needed to carry out daily activities Gradual loss of skills needed to carry out daily activities Progressive Progressive Dementia UK Report 2007

Dementia Deficits in Memory and Functional abilities, plus two more categories Memory Memory Functional abilities Functional abilities Language Language Perceptual skills Perceptual skills Attention Attention Constructive abilities Constructive abilities Orientation Orientation Problem solving Problem solving

Not all about memory 1. Age associated memory impairment Mild cognitive impairment Dementia

Dementia Diagnosis Neuropsychological assessments – e.g. MMSE, ADAS-cog Neuropsychological assessments – e.g. MMSE, ADAS-cog Clinical examination Clinical examination Collateral history Collateral history Brain scan Brain scan Blood tests Blood tests

Distribution pathology in typical AD (Braak and Braak 1991)

Focal dementia YOU DO NOT NEED IMAGING TO DISTINGUISH THESE CONDITIONS PATIENT 1 ALZHEIMER’S PATHOLOGY: HIPPOCAMPUS → memory sx PATIENT 3 ALZHEIMERS OR FTD PATHOLOGY: LEFT POSTERIOR SUPERIOR TEMPORAL LOBE → non-fluent aphasia PATIENT 4 FTD PATHOLOGY: LEFT LATERAL TEMPORAL LOBE → fluent aphasia L R PATIENT 2 ALZHEIMER’S PATHOLOGY: PARIETAL LOBE → spatial sx

Dementia Alzheimer’s Disease Alzheimer’s Disease Vascular Dementia Vascular Dementia Dementia with Lewy Bodies Dementia with Lewy Bodies Frontotemporal lobe dementias Frontotemporal lobe dementias Others 55 % 20 % 15 % 5 %

Alzheimer’s Slow insidious onset Slow insidious onset Progressive decline Progressive decline Early changes in personality – ‘depression’, agitation Early changes in personality – ‘depression’, agitation Positive family history Positive family history

Alzheimer’s - Pathology Loss of cholinergic neurones Loss of cholinergic neurones Amyloid plaques Amyloid plaques Neurofibrillary tangles of Tau proteins Neurofibrillary tangles of Tau proteins

Vascular Dementia Often abrupt onset Often abrupt onset Step-wise progression Step-wise progression Focal neurological signs or symptoms Focal neurological signs or symptoms Evidence of cerebrovascular disease on brain scan Evidence of cerebrovascular disease on brain scan Emotional lability Emotional lability Early presence of gait disturbance Early presence of gait disturbance

Dementia with Lewy Bodies (DLB) Sits somewhere between Alzheimer’s and Parkinson’s Sits somewhere between Alzheimer’s and Parkinson’s 2 out of 3 of 2 out of 3 of Spontaneous features of Parkinsonism Spontaneous features of Parkinsonism Visual hallucinations Visual hallucinations Fluctuating course Fluctuating course Supporting features Supporting features Recurrent falls / syncope Recurrent falls / syncope Neuroleptic sensitivity - 70 % patients affected Neuroleptic sensitivity - 70 % patients affected Systematized delusions Systematized delusions

Treatment of Dementia Education, support and signposting to services Disease modifying Symptomatic Drugs for behavioural disturbance

Dementia Treatment - Symptomatic Effects vs Slowing Disease Impairment Treatment Period EndBaseline Severe Mild Placebo Symptomatic Disease modifying (Ferris, 8/03)

Alzheimer’s Disease Cholinesterase inhibitors Donepezil, Rivastigmine, Galantamine Glutamate receptor antagonist Memantine

Vascular Dementia Secondary prevention for stroke - Disease Modifying Secondary prevention for stroke - Disease Modifying Antiplatelet therapy or anticoagulation if AF Antiplatelet therapy or anticoagulation if AF Statin Statin Perindopril +/- Indapamide Perindopril +/- Indapamide Promote healthy lifestyle with regard to diet, exercise, good diabetic control, smoking cessation, etc. Promote healthy lifestyle with regard to diet, exercise, good diabetic control, smoking cessation, etc.

Case Study Arthur has recently attended the memory clinic at the hospital and has been diagnosed with dementia of the ‘mixed type’. Arthur has a mini-mental state examination (MMSE) of 23. He has a background history of hypertension and has fallen twice in the last year. Amitryptiline 50 mg nocte, Simvastatin 20 mg nocte, Zopiclone 7.5 mg nocte, Bendroflumethiazide 2.5 mg od, Aspirin 75 mg od Suggest some possible options for management.

The Future Alzheimer’s: drugs spontaneous to disease-modifying..multidrug Vascular: earlier recognition and aggressive treatment Parkinsons: disease modifying drugs: single drug Legal situation: living will, Preferred priority care / living Societal moral legal debate for treatment of advanced dementia Ageism

Acknowledgements Dr John Whitear Geriatrician Dr Lucy Coward Neurologist S/N Christine Timms S/N Jackie Smith